Boehringer Ingelheim has acquired an exclusive license for a preclinical, small molecule program from Sitryx Therapeutics, a clinical-stage biopharmaceutical company. The program offers a novel, oral, potentially disease-modifying treatment approach across multiple autoimmune and inflammatory disease indications. Under the terms of the agreement, Sitryx grants Boehringer an exclusive global license to the multiple candidates and associated intellectual property within this small molecule inhi...